---
title: "Nanjing Leads Biolabs Calls 2026 AGM and Seeks Fresh Share Issuance Mandate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284020496.md"
description: "Nanjing Leads Biolabs Co., Ltd. has scheduled its 2026 AGM for May 15, 2026, to review its 2025 performance and governance plans. Shareholders will vote on the board’s reports, profit distribution, and appointing Dr. Wu Fenglan as a non-executive director. The board seeks a mandate to issue up to 20% of share capital for financing flexibility. The latest analyst rating for the stock (HK:9887) is a Buy with a target price of HK$100.50. Nanjing Leads Biolabs specializes in innovative biological drugs and is listed in Hong Kong with a market cap of HK$16.28B."
datetime: "2026-04-24T14:09:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284020496.md)
  - [en](https://longbridge.com/en/news/284020496.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284020496.md)
---

# Nanjing Leads Biolabs Calls 2026 AGM and Seeks Fresh Share Issuance Mandate

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has provided an update.

Nanjing Leads Biolabs Co., Ltd., a Hong Kong-listed Chinese biopharmaceutical firm specializing in innovative biological drugs, has convened its annual general meeting for May 15, 2026 in Nanjing to review its 2025 performance and set governance plans for 2026. Shareholders will consider the board’s 2025 work report, final financial and annual reports, the profit distribution plan, and the directors’ remuneration for 2026.

The meeting will also vote on appointing Dr. Wu Fenglan as a non-executive director and reappointing Ernst & Young as auditor for 2026, reinforcing the company’s corporate governance framework. In addition, the board seeks a general mandate to issue up to 20% of the company’s share capital during a defined period, a move that would provide financing flexibility and potential support for future growth initiatives, while impacting existing shareholders’ dilution and capital structure.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$100.50 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

**More about Nanjing Leads Biolabs Co., Ltd. Class H**

Nanjing Leads Biolabs Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong, engaged in the research, development and commercialization of innovative biological drugs. It operates in the life sciences sector, focusing on advanced therapies for medical needs in domestic and international markets, and is governed by a board of directors and external auditors in line with capital market standards.

**Average Trading Volume:** 904,705

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$16.28B

### Related Stocks

- [09887.HK](https://longbridge.com/en/quote/09887.HK.md)

## Related News & Research

- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [The Seed 100: The best early-stage investors of 2026](https://longbridge.com/en/news/286743225.md)
- [Wide postpones 2026 annual meeting to June 17; proxy voting deadline June 16](https://longbridge.com/en/news/286911986.md)
- [Acenta Group delays Q1 interim report release to May 29, 2026](https://longbridge.com/en/news/287031560.md)
- [Crombie Reit Announces May 2026 Monthly Distribution | CROMF Stock News](https://longbridge.com/en/news/286603129.md)